Cryo Cell International Inc (CCEL) Stock Analysis and Metrics

Cryo Cell International

NYSE: CCEL

$3.46 ▼ -0.02 (-0.57%)

At close: Jul 17, 2026 · 2:33 PM UTC

Financial Ratios

Market Cap484,993.46

P/E-0.18

P/S0.02

Div. Yield2.50

ROIC (Qtr)0.00

Total Debt (Qtr)2.48 Mn

Revenue Growth (1y) (Qtr)-3.59

Add ratio to table…

About

Cryo-Cell International, Inc. is organized in three reportable segments: cellular processing and cryogenic storage for family use, the manufacture of PrepaCyte® CB Processing System units, and cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company provides services for the collection, processing, testing, and long-term storage of umbilical cord blood and tissue stem cells. It operates from its headquarters in Oldsmar, Florida, and utilizes a technologically advanced facility in Durham, North Carolina for specimen storage.

The company generates revenue through processing and storage fees for umbilical cord blood and tissue specimens, annual storage fees, and prepaid storage plans. It also earns income from the manufacture and sale of PrepaCyte® CB Processing System units used to process umbilical cord blood stem cells. Additionally, revenue is derived from public cord blood banking activities, including the distribution of units through the National Marrow Donor Program, and from third-party biorepository services such as ExtraVault.

The company operates through the following segments:

• Cellular processing and cryogenic storage for family use: This segment focuses on the collection, processing, testing, and cryopreservation of umbilical cord blood and tissue stem cells for individual family use. It offers services including the collection kit, processing, testing, and first-year storage, followed by annual storage fees or prepaid plans. The segment utilizes the PrepaCyte® CB Processing System for stem cell recovery and red blood cell depletion.

• Manufacture of PrepaCyte® CB Processing System units: This segment involves the production of the PrepaCyte® CB Processing System, a medical device used to process umbilical cord blood stem cells prior to banking. The system is a 510(k) cleared Class II device composed of three integrally attached processing and storage containers with separation media. It is designed to maximize recovery of healthy stem cells and provide superior red blood cell depletion compared to other methods.

• Cellular processing and cryogenic storage of umbilical cord blood stem cells for public use: This segment handles the processing and storage of donated umbilical cord blood units for public use through the National Marrow Donor Program. The company acquired substantially all assets of Cord:Use Cord Blood Bank, Inc. in June 2018 to establish this public inventory. The units are listed on the NMDP registry and distributed to transplant centers worldwide, with the company receiving cost recovery for units distributed.

Cryo-Cell International, Inc. holds a leadership position in the private cord blood banking industry as the world’s first private cord blood bank, having separated and stored stem cells since 1992. The company differentiates itself through its cGMP- and cGTP-compliant facility, AABB and FACT accreditations, and a 100% viability rate of specimens upon thaw since inception. It competes against approximately 25 other national private cord blood banks and believes its value-based pricing, superior customer service, and technical expertise provide a competitive advantage.

The company serves expectant parents seeking to preserve their newborn’s umbilical cord blood and tissue stem cells for potential future family use. It also serves patients in need of stem cell transplants through its public cord blood banking program, with units distributed via the National Marrow Donor Program to transplant centers in the United States and worldwide. Additionally, the company provides biorepository services to pharmaceutical companies and healthcare institutions through its ExtraVault facility.

Investment Thesis

▲ Bull case

The recent renewal of FACT accreditation through April 2029 reinforces Cryo Cell’s reputation for meeting the highest international standards in cord blood processing and storage. This credential is recognized by leading transplant centers and can be leveraged to justify premium pricing for private banking services. Families and physicians often view FACT accreditation as a trust signal that may improve conversion rates for new enrollments. The accreditation also opens doors to strategic partnerships with hospitals and research institutions that require proof of high quality compliance.
Cryo Cell holds exclusive rights to the PrepaCyte CB processing technology which is designed to maximize stem cell recovery and viability compared with legacy methods. This proprietary advantage can be monetized through licensing agreements with other banks or through higher service fees that reflect superior product quality. The technology also reduces processing waste and may lower the cost per unit over time as scale increases. Maintaining exclusivity protects the company from direct competition on the processing front and supports long term margin expansion.
The company is actively pursuing growth initiatives such as the ExtraVault service offering which provides additional storage options for cord tissue and other biologics. Expansion into international markets through partnerships with affiliates can increase the addressable customer base beyond the United States. Cryo Cell is also exploring opportunities to develop biopharmaceutical manufacturing capabilities and to operate clinics that administer cellular therapies derived from stored units. Furthermore the potential spin off of Celle Corp could unlock hidden value by separating the biotech assets from the core storage business allowing each entity to be valued on its own merits.
With over 250,000 cord blood and cord tissue specimens currently under storage Cryo Cell enjoys a recurring revenue stream from annual storage fees that is relatively predictable. The long term nature of these contracts creates a stable cash flow foundation that can support investment in growth projects. Increasing public awareness of the therapeutic potential of cord blood and favorable demographic trends in key markets are expected to drive steady inflows of new samples. As the storage base grows the company benefits from operating leverage which can improve profitability even if processing fees remain flat.
The acceptance of Cryo Cell’s compliance plan by NYSE American provides a clear pathway to regain listing standards and removes the immediate threat of delisting. The compliance period runs through September 9 2027 giving the company ample time to address the stockholders' deficit and to achieve profitability in the required fiscal years. Meeting these conditions will likely restore investor confidence and could lead to a re rating of the stock based on improved fundamentals. While the plan does not guarantee success it establishes a disciplined framework for cost control and revenue enhancement that can benefit operations regardless of the listing outcome.

The recent renewal of FACT accreditation through April 2029 reinforces Cryo Cell’s reputation for meeting the highest international standards in cord blood processing and storage. This credential is recognized by leading transplant centers and can be leveraged to justify premium pricing for private banking services. Families and physicians often view FACT accreditation as a trust signal that may improve conversion rates for new enrollments. The accreditation also opens doors to strategic partnerships with hospitals and research institutions that require proof of high quality compliance.
Cryo Cell holds exclusive rights to the PrepaCyte CB processing technology which is designed to maximize stem cell recovery and viability compared with legacy methods. This proprietary advantage can be monetized through licensing agreements with other banks or through higher service fees that reflect superior product quality. The technology also reduces processing waste and may lower the cost per unit over time as scale increases. Maintaining exclusivity protects the company from direct competition on the processing front and supports long term margin expansion.
The company is actively pursuing growth initiatives such as the ExtraVault service offering which provides additional storage options for cord tissue and other biologics. Expansion into international markets through partnerships with affiliates can increase the addressable customer base beyond the United States. Cryo Cell is also exploring opportunities to develop biopharmaceutical manufacturing capabilities and to operate clinics that administer cellular therapies derived from stored units. Furthermore the potential spin off of Celle Corp could unlock hidden value by separating the biotech assets from the core storage business allowing each entity to be valued on its own merits.
With over 250,000 cord blood and cord tissue specimens currently under storage Cryo Cell enjoys a recurring revenue stream from annual storage fees that is relatively predictable. The long term nature of these contracts creates a stable cash flow foundation that can support investment in growth projects. Increasing public awareness of the therapeutic potential of cord blood and favorable demographic trends in key markets are expected to drive steady inflows of new samples. As the storage base grows the company benefits from operating leverage which can improve profitability even if processing fees remain flat.
The acceptance of Cryo Cell’s compliance plan by NYSE American provides a clear pathway to regain listing standards and removes the immediate threat of delisting. The compliance period runs through September 9 2027 giving the company ample time to address the stockholders' deficit and to achieve profitability in the required fiscal years. Meeting these conditions will likely restore investor confidence and could lead to a re rating of the stock based on improved fundamentals. While the plan does not guarantee success it establishes a disciplined framework for cost control and revenue enhancement that can benefit operations regardless of the listing outcome.

▼ Bear case

Recent financial results show a troubling trend with quarterly revenue slipping from 7,970,000 to 7,680,000 and net income falling from 283 thousand to just 47 thousand in Q1 FY26. The full FY25 recorded a net loss of 2,400,000 after a 4,400,000 impairment charge that wrote down the value of public inventory to net realizable value. This impairment indicates that the company may have overstated the worth of its inventory assets and that future write downs remain possible. Persistent declines in top line earnings coupled with sizable one time charges raise doubts about the sustainability of the current business model.
The balance sheet shows a stockholders' deficit as of November 30 2025 which signals that liabilities exceed equity and raises concerns about the company’s ability to absorb further losses without additional financing. Net losses were recorded in two of the three most recent fiscal years ended November 30 2023 November 30 2024 and November 30 2025 indicating a pattern of underperformance that may limit access to capital markets. A weakened equity position could constrain the company’s capacity to invest in new technologies or to pursue acquisitions that might be necessary for long term growth. Creditors and suppliers may become less willing to extend terms if they perceive heightened financial risk.
The private cord blood banking industry faces intensifying competition from both established public banks and new entrants offering lower cost storage options or innovative value added services. Public banking programs often benefit from government subsidies and philanthropic support which can enable them to undercut private pricing while still maintaining quality standards. New private players may leverage aggressive marketing or technological advancements to capture market share especially among price sensitive consumers. As competition intensifies Cryo Cell may be forced to reduce fees or to increase spending on differentiation efforts which could compress margins and impede profitability.
Regulatory and intellectual property risks loom large given the company’s dependence on license agreements for its umbilical cord blood and cord tissue technologies and the need to enforce patents that protect the PrepaCyte CB process. Any successful challenge to these IP rights could allow competitors to replicate the processing advantage eroding Cryo Cell’s differentiator. Changes in FDA regulations or updates to cGMP and cGTP requirements could impose additional compliance costs or necessitate costly process modifications. The enforceability of royalty agreements with partners is also uncertain and a failure to collect expected royalties would directly impact the bottom line.
Macro economic headwinds such as declining birth rates in key markets and pressure on discretionary healthcare spending could suppress demand for new cord blood storage contracts. In addition the company remains subject to NYSE American listing requirements and failure to meet the compliance plan by the September 9 2027 deadline could trigger delisting proceedings which would likely hurt liquidity and increase the cost of capital. Even if the plan is accepted the ongoing monitoring and reporting burden may divert management attention from core operational priorities. Investors may view the listing risk as a overhang that depresses the share price until tangible progress is demonstrated.

Recent financial results show a troubling trend with quarterly revenue slipping from 7,970,000 to 7,680,000 and net income falling from 283 thousand to just 47 thousand in Q1 FY26. The full FY25 recorded a net loss of 2,400,000 after a 4,400,000 impairment charge that wrote down the value of public inventory to net realizable value. This impairment indicates that the company may have overstated the worth of its inventory assets and that future write downs remain possible. Persistent declines in top line earnings coupled with sizable one time charges raise doubts about the sustainability of the current business model.
The balance sheet shows a stockholders' deficit as of November 30 2025 which signals that liabilities exceed equity and raises concerns about the company’s ability to absorb further losses without additional financing. Net losses were recorded in two of the three most recent fiscal years ended November 30 2023 November 30 2024 and November 30 2025 indicating a pattern of underperformance that may limit access to capital markets. A weakened equity position could constrain the company’s capacity to invest in new technologies or to pursue acquisitions that might be necessary for long term growth. Creditors and suppliers may become less willing to extend terms if they perceive heightened financial risk.
The private cord blood banking industry faces intensifying competition from both established public banks and new entrants offering lower cost storage options or innovative value added services. Public banking programs often benefit from government subsidies and philanthropic support which can enable them to undercut private pricing while still maintaining quality standards. New private players may leverage aggressive marketing or technological advancements to capture market share especially among price sensitive consumers. As competition intensifies Cryo Cell may be forced to reduce fees or to increase spending on differentiation efforts which could compress margins and impede profitability.
Regulatory and intellectual property risks loom large given the company’s dependence on license agreements for its umbilical cord blood and cord tissue technologies and the need to enforce patents that protect the PrepaCyte CB process. Any successful challenge to these IP rights could allow competitors to replicate the processing advantage eroding Cryo Cell’s differentiator. Changes in FDA regulations or updates to cGMP and cGTP requirements could impose additional compliance costs or necessitate costly process modifications. The enforceability of royalty agreements with partners is also uncertain and a failure to collect expected royalties would directly impact the bottom line.
Macro economic headwinds such as declining birth rates in key markets and pressure on discretionary healthcare spending could suppress demand for new cord blood storage contracts. In addition the company remains subject to NYSE American listing requirements and failure to meet the compliance plan by the September 9 2027 deadline could trigger delisting proceedings which would likely hurt liquidity and increase the cost of capital. Even if the plan is accepted the ongoing monitoring and reporting burden may divert management attention from core operational priorities. Investors may view the listing risk as a overhang that depresses the share price until tangible progress is demonstrated.

Segments Breakdown of Revenue (2025)

Peer Comparison

Companies in the Medical Care Facilities

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	HCA	HCA Healthcare, Inc.	87.94 Bn	11.25	1.15	48.02 Bn
2	CHE	Chemed Corp	18.08 Bn	51.68	7.12	0.09 Bn
3	THC	Tenet Healthcare Corp	16.59 Bn	9.74	0.77	13.21 Bn
4	DVA	Davita Inc.	15.37 Bn	14.02	1.10	10.63 Bn
5	EHC	Encompass Health Corp	10.07 Bn	654.20	1.66	2.57 Bn
6	ENSG	Ensign Group, Inc	9.52 Bn	27.18	1.81	0.14 Bn
7	UHS	Universal Health Services Inc	9.19 Bn	6.05	0.52	4.71 Bn
8	PACS	PACS Group, Inc.	6.96 Bn	28.55	1.28	0.05 Bn

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password